Pfizer Corporation

Amgen Fremont Inc.

Medimmune Limited

Warner-lambert Company

Abgenix, Inc.

Pfizer Products Inc.

Vahe Bedian

Ian Nevin Foltz

Xiao-Chi Jia

Mary Haak-Frendscho

Jose Corvalan

Xiao Feng

Ronald P Gladue

Joseph Edwin Low

Madhav Narasimha Devalaraja

James Leslie Mobley

Larry L Green

Shama Kajiji

Kevin G Coleman

Neil R Michaud

Gary Borzillo

James A Thomson

Sirid-Aimee Kellermann

David Jenkins

Michael Aidan North

Simon Thomas Barry

Xin Jiang

Sirid-Aimée Kellermann

Dana Dan Hu-Lowe

Jianying Wang

Grant Raymond Wickman

Jingchuan Zhang

Karin Kristina Amundson

Shannon Marie Karlicek

Herren Wu

Ralph Raymond Minter

William Dall'Acqua

Andrew Grier Buchanan

Michael A Bowen

Bruce D Cohen

Shelley Sims Belouski

Julie Rinkenberger

Jeffrey Brown

Sirid Aimee Kellerman

Jaspal Singh Kang

Bradley John Hedberg

Avril Alfred

Qing Zhou

James Arthur Thomson

Chris Stannard

Shelly Sims Belouski

Sirid-Aimée Kellerman

Ronald Paul Gladue

John Daniel Cusmano

Bruce David Cohen

Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.

Stabilized angiopoietin-2 antibodies and uses thereof

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

Antibodies to M-CSF

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

Human monoclonal antibodies to activin receptor-like kinase-1

The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.

Nucleic acid molecule encoding target antibodies directed to DLL4

Targeted binding agents, such antibodies directed to the antigen &#x3b1;V&#x3b2;6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen &#x3b1;V&#x3b2;6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.

Antibodies directed to &#x3b1;V&#x3b2;6 and uses thereof

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

Treatment methods using c-Met antibodies

Method of treating a malignant tumor by administering antibodies directed to DLL4

Antibodies to c-Met

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses

Targeted antibodies directed to DLL4

Nucleic acid molecules encoding antibodies to M-CSF

Growing community of inventors

East Lyme, CT, United States of America

Vahe Bedian